entertainment -WSS

entertainment

author：knowledge 2025-09-06 03:36:38 Page View：699

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Lawmakers consider Medicare pay reforms for doctors
Next article： Jerome Adams on the need for new antivirals for Covid

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Pharmacists can make shortage drugs, but at what cost?

AdobePharmacistsincreasinglyarebeingaskedtomakedrugsinbulkforhospitalsthatareinshortsupply,andthey’r

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Donor acceptance rates hint at racial, gender bias in heart transplants: study

AdobeWhenapatientisgoingthroughend-stageheartfailure,thebesttreatmentistogetahearttransplant.Thebasi